Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.39 |
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186802 | 0.86 | HSD17B10 (0.31) | HTR2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL20186692 | 0.72 | HSD11B1 (0.34) | ALDH1A1MAPT | |
| SCHEMBL20186853 | 0.69 | HTR2A (0.72) | HTR2AHTR2C | |
| SCHEMBL20186463 | 0.67 | HTR6 (0.36) | KDM4EALDH1A1LMNAGAA | |
| SCHEMBL11282704 | 0.61 | ALDH1A1 (0.46) | HTR2AHTR2CKDM4EALDH1A1LMNA | |
| SCHEMBL16299571 | 0.61 | HTR2A (0.41) | HTR2AHTR2CKDM4EALDH1A1LMNA | |
| SCHEMBL20186653 | 0.61 | HTR2A (0.67) | HTR2AHTR2C | |
| SCHEMBL10989925 | 0.57 | HSD17B10 (0.60) | HTR2AHTR2CKDM4EALDH1A1LMNA | |
| SCHEMBL765089 | 0.57 | HTR2A (0.75) | HTR2AHTR2C | |
| SCHEMBL764079 | 0.57 | HTR2A (1.00) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288921-B1 | POLYCYCLIC INDOLINE AND INDOLENINE COMPOUNDS | UNIV COLORADO REGENTS (US) | 2022-06-15 | — | — | EP | disclosed |
| US-10253024-B2 | Polycyclic indoline and indolenine compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180148442-A1 | Polycyclic Indoline and Indolenine Compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253024-B2 | Polycyclic indoline and indolenine compounds | IDO1, IDO2, INMT | HTR2A 148/4885HTR2C 160/4885KDM4E 2790/4885 |
| US-20180148442-A1 | Polycyclic Indoline and Indolenine Compounds | IDO1, IDO2, INMT | HTR2A 148/4885HTR2C 160/4885KDM4E 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.